Pre-made Bavituximab benchmark antibody ( Whole mAb, anti-Phosphatidylserine therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bavituximab biosimilar, Whole Mab: Anti-Phosphatidylserine therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C.[3] The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-051-1mg	1mg	3090
GMP-Bios-ab-051-10mg	10mg	Inquiry
GMP-Bios-ab-051-100mg	100mg	Inquiry
GMP-Bios-ab-051-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bavituximab biosimilar, Whole Mab: Anti-Phosphatidylserine therapeutic antibody
INN Name	Bavituximab
Target	Phosphatidylserine
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2006
Year Recommended	2007
Companies	Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours
Conditions Discontinued	Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer
Development Tech	na